{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:08:07Z","timestamp":1792728487682,"version":"4.5.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Buprenorphine treatment for opioid use disorder (OUD) has more than doubled since 2009. However, current US Food and Drug Administration buprenorphine dosing guidelines are based on studies among people using heroin, prior to the emergence of fentanyl in the illicit drug supply.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the association between buprenorphine dose and time to treatment discontinuation during a period of widespread fentanyl availability.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study used statewide Rhode Island Prescription Drug Monitoring Program data. Participants were Rhode Island residents initiating buprenorphine treatment for OUD between October 1, 2016, and September 30, 2020. Data analysis was performed from December 9, 2022, to August 10, 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Daily dose of buprenorphine (16 mg and 24 mg) defined starting on the day of initiation based on total quantity and days\u2019 supply dispensed. Patients were censored on any dose change.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Buprenorphine treatment discontinuation in the 180 days following initiation, defined as a gap in treatment of more than 27 days based on prescription fill dates and days\u2019 supply. Kaplan-Meier and Cox regression survival analyses were conducted to estimate the association between buprenorphine dose and time to treatment discontinuation, controlling for potential informative censoring and measured potential confounders.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 6499 patients initiating buprenorphine treatment for OUD, most were aged 25 to 44 years (57%; n\u2009=\u20093682), were male (61%; n\u2009=\u20093950), and had private (47%; n\u2009=\u20093025) or Medicaid (33%; n\u2009=\u20092153) insurance. More than half of patients were prescribed a daily dose of interest at initiation (16 mg: 50%; n\u2009=\u20093264; 24 mg: 10%; n\u2009=\u2009668). In Kaplan-Meier analyses, 58% of patients discontinued buprenorphine treatment within 180 days (16 mg: 59% vs 24 mg: 53%; log-rank test\n P<\/jats:italic>\n \u2009=\u2009.005). In Cox regression analyses, patients prescribed a dose of 16 mg had a greater risk of treatment discontinuation than those prescribed 24 mg (adjusted hazard ratio, 1.20; 95% CI, 1.06-1.37).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients initiating buprenorphine treatment from 2016 to 2020, patients prescribed a 24 mg dose of buprenorphine remained in treatment longer than those prescribed 16 mg. The value of higher buprenorphine doses than currently recommended needs to be considered for improving retention in treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.34540","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T11:01:32Z","timestamp":1695034892000},"page":"e2334540","source":"Crossref","is-referenced-by-count":116,"title":["Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl"],"prefix":"10.1001","volume":"6","author":[{"given":"Laura C.","family":"Chambers","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Hallowell","sequence":"additional","affiliation":[{"name":"Substance Use Epidemiology Program, Rhode Island Department of Health, Providence"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Zullo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor J.","family":"Paiva","sequence":"additional","affiliation":[{"name":"Substance Use Epidemiology Program, Rhode Island Department of Health, Providence"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Berk","sequence":"additional","affiliation":[{"name":"Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Gaither","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan J.","family":"Hampson","sequence":"additional","affiliation":[{"name":"Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca L.","family":"Beaudoin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Brown University, Providence, Rhode Island"},{"name":"Department of Emergency Medicine, Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S.","family":"Wightman","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"issue":"2","key":"zoi230990r2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi230990r3","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"zoi230990r4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.03.006","article-title":"The impact of buprenorphine\/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.","volume":"139","author":"Edelman","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"zoi230990r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder.","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi230990r7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"zoi230990r11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A neuropharmacological model to explain buprenorphine induction challenges.","volume":"80","author":"Greenwald","year":"2022","journal-title":"Ann Emerg Med"},{"issue":"1","key":"zoi230990r12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.v30.1","article-title":"Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone.","volume":"30","author":"Antoine","year":"2021","journal-title":"Am J Addict"},{"issue":"5","key":"zoi230990r13","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/add.v114.5","article-title":"What should clinicians do as fentanyl replaces heroin?","volume":"114","author":"Bisaga","year":"2019","journal-title":"Addiction"},{"key":"zoi230990r14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: Buprenorphine experiences in an era of illicit fentanyl.","volume":"74","author":"Silverstein","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi230990r15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/JCP.0000000000001308","article-title":"Treatment of opioid use disorder attributed to fentanyl with high-dose buprenorphine: a case report.","volume":"41","author":"Baca-Atlas","year":"2021","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"zoi230990r16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dar.v39.2","article-title":"High-dose buprenorphine for treatment of high potency opioid use disorder.","volume":"39","author":"Danilewitz","year":"2020","journal-title":"Drug Alcohol Rev"},{"issue":"4","key":"zoi230990r17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1124\/mol.110.066613","article-title":"\u00b5-Opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization.","volume":"78","author":"McPherson","year":"2010","journal-title":"Mol Pharmacol"},{"issue":"625","key":"zoi230990r18","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci Signal"},{"issue":"1","key":"zoi230990r19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u00b5-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects.","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat Commun"},{"key":"zoi230990r20","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: a review.","author":"Grande","year":"2023","journal-title":"J Addict Med"},{"key":"zoi230990r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108317","article-title":"Adherence to buprenorphine: an analysis of prescription drug monitoring program data.","volume":"216","author":"Pizzicato","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi230990r22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.2014.109.issue-1","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial.","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"5","key":"zoi230990r23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial.","volume":"164","author":"Kakko","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"2","key":"zoi230990r24","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right.","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"1-3","key":"zoi230990r25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.drugalcdep.2007.10.017","article-title":"Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres.","volume":"94","author":"Leonardi","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi230990r27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome.","volume":"31","author":"Fareed","year":"2012","journal-title":"J Addict Dis"},{"issue":"12","key":"zoi230990r28","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/pme.12520","article-title":"Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.","volume":"15","author":"Daitch","year":"2014","journal-title":"Pain Med"},{"issue":"10","key":"zoi230990r30","first-page":"62","article-title":"Accidental drug overdose deaths in Rhode Island: January 1, 2016-July 31, 2020.","volume":"103","author":"Hallowell","year":"2020","journal-title":"R I Med J (2013)"},{"issue":"7","key":"zoi230990r31","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/ajad.v24.7","article-title":"Treatment outcomes in opioid dependent patients with different buprenorphine\/naloxone induction dosing patterns and trajectories.","volume":"24","author":"Jacobs","year":"2015","journal-title":"Am J Addict"},{"issue":"2","key":"zoi230990r32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s11419-022-00624-y","article-title":"Non-fentanyl-derived synthetic opioids emerging during recent years.","volume":"40","author":"Hasegawa","year":"2022","journal-title":"Forensic Toxicol"},{"issue":"7","key":"zoi230990r33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1021\/acschemneuro.1c00064","article-title":"Synthesis, chemical characterization, and \u00b5-opioid receptor activity assessment of the emerging group of \u201cnitazene\u201d 2-benzylbenzimidazole synthetic opioids.","volume":"12","author":"Vandeputte","year":"2021","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"zoi230990r34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13722-019-0139-3","article-title":"Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.","volume":"14","author":"Godersky","year":"2019","journal-title":"Addict Sci Clin Pract"},{"issue":"7","key":"zoi230990r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder.","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi230990r6","author":"Weiss","year":"2008"},{"key":"zoi230990r1","unstructured":"Ahmad? FB, Cisewski? JA, Rossen? LM, Sutton? P. Provisional Drug Overdose Death Counts. National Center for Health Statistics. February 15, 2023. Accessed August 18, 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi230990r8","unstructured":"Sublingual Film? SUBOXONE. Prescribing information. Reckitt Benckiser Pharmaceuticals Inc; 2010. Accessed August 18, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022410s000lbl.pdf"},{"key":"zoi230990r9","unstructured":"Sublingual Tablets? SUBOXONE. Prescribing information. Reckitt Benckiser Pharmaceuticals Inc; 2018. Accessed August 18, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020733s022lbl.pdf"},{"key":"zoi230990r10","unstructured":"Sublingual Tablets? SUBUTEX. Prescribing information. Indivior Inc; 2018. Accessed August 18, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020732s018lbl.pdf"},{"key":"zoi230990r26","unstructured":"US Food and Drug Administration. NDA 22-410 Suboxone (Buprenorphine\/Naloxone) Sublingual Film. 2009. Accessed August 18, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022410Orig1s000MedR.pdf"},{"key":"zoi230990r29","unstructured":"US Drug Enforcement Administration. National Forensic Laboratory Information System - Drug 2021 Annual Report. 2022. Accessed August 18, 2023. https:\/\/www.nflis.deadiversion.usdoj.gov\/nflisdata\/docs\/NFLISDrug_2021AnnualReport.pdf."},{"key":"zoi230990r36","unstructured":"US Centers for Medicare & Medicaid Services. Quality ID #468 (NQF 3175): Continuity of Pharmacotherapy for Opioid Use Disorder (OUD). 2019. Accessed August 18, 2023. https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2019_Measure_468_MIPSCQM.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809633\/chambers_2023_oi_230990_1694192882.0914.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T11:01:38Z","timestamp":1695034898000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.34540","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]}}}